Thelansis

 Metastatic colorectal cancer (mCRC) stands as a prominent contributor to cancer-related deaths, with approximately 30–40% of patients presenting with metastatic disease at diagnosis. Notably, HER2 positivity is rare, affecting less than 5% of our mCRC patient cohort. The detection of HER2 overexpression in CRC involves immune-histochemical (IHC) staining for HER2 protein, in-situ hybridization (ISH) for gene amplification, or reverse transcription polymerase chain reaction (RT-PCR) for HER2 RNA overexpression. Furthermore, HER2 amplification and mutations in KRAS, NRAS, and BRAF typically do not co-occur in advanced CRC, with KRAS exon two wild-type mCRC exhibiting a potential enrichment for HER2 amplification, found in approximately 4% to 9% of cases. The overall survival duration is approximately 24.1 months, ranging from 20.3 to 36.7 months. A noteworthy advancement in treatment is the FDA approval of the Tukysa and Herceptin combination, marking the first approved therapy for ...

 Colorectal cancer (CRC) is the third commonest cause of cancer death. It is estimated that 150,750 new cases of CRC will be diagnosed in the US in 2020. Approximately 25% of patients have metastatic disease at diagnosis, and approximately 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. HER2 overexpression in CRC was detected by immune-histochemical (IHC) staining for HER2 protein and in-situ hybridization (ISH) for gene amplification or reverse transcription polymerase chain reaction (RT-PCR) for overexpression of HER2 RNA. HER2 amplification and KRAS, NRAS, and BRAF mutations are mutually exclusive in advanced CRC. In addition, KRAS exon two wild-type metastatic CRC appears to enrich for HER2 amplification in the range of 4% to 9% of cases. Thelansis’s “HER2-Positive Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug ut...